Journal of the American Society of Hypertension
Volume 3, Issue 5 , Pages 315-320 , September 2009

Renal plasma flow: glomerular filtration rate relationships in man during direct renin inhibition with aliskiren

  • Andres E. Splenser, MD

      Affiliations

    • Department of Radiology and Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
    • ,
  • Naomi D.L. Fisher, MD

      Affiliations

    • Department of Radiology and Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
    • ,
  • A.H. Jan Danser, MD

      Affiliations

    • Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Norman K. Hollenberg, MD, PhD

      Affiliations

    • Department of Radiology and Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
    • Corresponding Author InformationCorresponding author: Norman K. Hollenberg, MD, PhD, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115. Tel: 617-732-6682; fax: 617-232-2864.

Received 14 May 2009 ,Accepted 29 June 2009.

References 

  1. Carey RM, Padia SH. Physiology and regulation of the renin-angiotensin-aldosterone system. In:  Singh AK,  Williams GH editor. Textbook of nephro-endocrinology. San Diego, California: Elsevier; 2009;p. 147–165
  2. Navar LG, Bell PD, Evan AP, Andreoli TE, Hoffman JF, Fanestil DD, et al. The regulation of glomerular filtration rate in mammalian kidneys. In: Physiology of membrane disorders. New York, New York: Plenum Publishing; 1986;p. 637–667
  3. Hollenberg NK, Williams GH, Taub KJ, Ishikawa I, Brown C, Adams DF. Renal vascular response to interruption of the renin-angiotensin system in normal man. Kidney Int. 1977;12:285–293
  4. Fisher NDL, Danser JAH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199–3205
  5. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest. 1983;72:2115–2124
  6. Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, et al. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension. 1994;23:44–51
  7. Menard J, Guyene TT, Peyrard S, Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertension. 2006;24:529–534
  8. Derkx FH, Deinum J, Lipovski M, Verhaar M, Fischli W, Schalekamp MA. Nonproteolytic “activation” of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. J Biol Chem. 1992;267:22837–22842
  9. Danser AH, Deinum J. Renin, prorenin, and the putative (pro)renin receptor. Hypertension. 2005;46:1069–1076
  10. Nussberger J, Fasanella DT, Porchet M, Waeber B, Brunner DB, Brunner HR, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol. 1987;9:39–44
  11. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension. 1986;8:476–482
  12. Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci. 1988;42:1683–1688
  13. Hollenberg NK, Price DA, Fisher NDL, Lansang MC, Perkins B, Gordon MS, et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int. 2003;63:172–178
  14. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278:F817–F822
  15. Hladunewich MA, Lafayette RA, Derby GC, Blouch KL, Bialek JW, Druzin ML, et al. The dynamics of glomerular filtration in the puerperium. Am J Physiol Renal Physiol. 2004;286:F496–F503
  16. Milne JE, Lindheimer MD, Davison JM. Glomerular heterosporous membrane modeling in third trimester and postpartum before and during amino acid infusion. Am J Physiol Renal Physiol. 2002;282:F170–F175
  17. Oken DE. An analysis of glomerular dynamics in rat, dog, and man. Kidney Int. 1982;22:136–145
  18. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004;65:30–39
  19. Wang L, Flannery PJ, Spurney RF. Characterization of angiotensin II-receptor subtypes in podocytes. J Lab Clin Med. 2003;142:313–321
  20. Ritt M, Ott C, Raff U, Schneider MP, Schuster I, Hilgers KF, et al. Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. Am J Kidney Dis. 2009;53:281–289
  21. Thachil J. Nitric oxide depletion is responsible for the adverse effects of vascular endothelial growth factor inhibitors. Nat Clin Pract Nephrol. 2008;4:536–537
  22. Guan Z, Osmond DA, Inscho EW. P2X receptors as regulators of the renal microvasculature. Trends Pharmacol Sci. 2007;28:646–652
  23. Faulhaber-Walter R, Chen L, Oppermann M, Kim SM, Huang Y, Hiramats N, et al. Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J Am Soc Nephrol. 2008;19:722–730
  24. Phipps JA, Feener EP. The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney. Kidney Int. 2008;73:1114–1119
  25. Vieitez P, Gomez O, Uceda ER, Vera ME, Molina-Holgado E. Systemic and local effects of Angiotensin II blockade in experimental diabetic nephropathy. J Renin Angiotensin Aldosterone Syst. 2008;9:96–102
  26. Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int. 2008;74:1128–1138
  27. Dubey RK, Jackson EK. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol. 2001;280:F365–F388
  28. Busse R, Fleming I. Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol Sci. 2003;24:24–29

 This study was supported by Novartis Pharmaceuticals, Inc and the National Institutes of Health Grant Nos. T32 HL 07609 and 1P50ML53000-01.

 Conflict of interest: none.

PII: S1933-1711(09)00094-1

doi: 10.1016/j.jash.2009.06.004

Journal of the American Society of Hypertension
Volume 3, Issue 5 , Pages 315-320 , September 2009

Article Tools

* Image Usage & Resolution